EGFR and non-small cell lung carcinoma: Subgroup analyses revealed prolonged OS in patients with Karnofsky performance status (KPS) ≥60 versus <60 (14.4 vs 9.0 months, P=0.0022) and those receiving Bevacizumab therapy versus not (19.2 vs 10.5 months, P=0.0011).<h4>Conclusions</h4>IP exhibits promising efficacy and manageable toxicity in EGFR-mutated NSCLC-LM patients.